A series of cardiometabolic-related news items has been observed from Beta Bionics, Insulet, Lilly, and Zealand Pharma. Below, FENIX provides highlights and insights on the respective news items.
A series of cardiometabolic-related news items have been observed from Lilly, Beta Bionics, Tandem Diabetes Care, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Novo Nordisk partnered with 9amHealth (view press release) and Form Health (view press release) for virtual care through NovoCare; and American Regent announced the launch of Gvoke VialDx as diagnostic aid during radiological exams (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Tandem Diabetes Care, Skye Bioscience, Novo Nordisk, Arrowhead, Gilead, Xeris, Viatris, Biocon, and 89bio. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Insulet, Senseonics, and MetaVia. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Lilly, Dexcom, Sanofi, AbbVie, Alnylam Pharmaceuticals, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.
Novo Nordisk presented results from the REDEFINE 1 and 2 cagrisema Ph3 trials at ADA 2025 (view press release); and the REDEFINE 1 (view publication) and REDEFINE 2 (view publication) results were simultaneously published in the NEJM. Following the readout, Novo hosted its ADA 2025 Investor Event and provided updates across its pipeline, including cagrisema, 7.2mg semaglutide, and amycretin. Below, FENIX provides highlights and insights from the REDEFINE presentation and investor webcast.
In the fourth installment of FENIX’s Obesity Spotlight Series, FENIX has conducted a deep dive analysis of Novo Nordisk’s obesity pipeline and strategy with a particular focus on the potential successor to semaglutide. The analysis includes an overview of Novo’s partnership/acquisition history as the company looks to fuel its next wave of obesity innovation and maintain its position in the increasingly crowded obesity market.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, Zealand Pharma, FDA/OFA, Lilly, MannKind, Xeris, and Viatris. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic news items have been observed: Beta Bionics hosted its Q1 ‘25 earnings call (press release; slides); and MetaVia announced full results from its Ph2 DA-1241 study in MASH (press release; view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.